The p38 mitogen-activated protein kinase inhibitor SB203580 can antagonise P2X7 receptor-mediated responses.

被引：0
|
作者：
Michel, D [1 ]
Thompson, KM [1 ]
Humphrey, PPA [1 ]
机构：
[1] Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2001年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
218P
引用
收藏
页码：U112 / U112
页数：1
相关论文
共 50 条
  • [1] Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580
    Kalmes, A
    Deou, J
    Clowes, AW
    Daum, G
    FEBS LETTERS, 1999, 444 (01) : 71 - 74
  • [2] Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase
    Ward, KW
    Proksch, JW
    Azzarano, LM
    Mumaw, JA
    Roethke, TJ
    Stelman, GJ
    Walsh, MJ
    Zeigler, KS
    McSurdy-Freed, JE
    Kehler, JR
    Chokshi, J
    Levy, MA
    Smith, BR
    XENOBIOTICA, 2001, 31 (11) : 783 - 797
  • [3] Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580
    Koranteng, RD
    Swindle, EJ
    Davis, BJ
    Dearman, RJ
    Kimber, I
    Flanagan, BF
    Coleman, JW
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 137 (01): : 81 - 87
  • [4] P38 mitogen-activated protein kinase inhibitor SB203580 has a bi-directional effect on iNOS expression and NO production
    Lahti, A
    Kankaanranta, H
    Moilanen, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 454 (2-3) : 115 - 123
  • [5] Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells
    Lin, ZS
    Crockett, DK
    Jenson, SD
    Lim, MS
    Elenitoba-Johnson, KSJ
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (08) : 820 - 833
  • [6] p38 mitogen activated protein kinase inhibitor SB203580 attenuate the mechanical allodynia in neuropathic pain model.
    Mizokoshi, A
    Tsuda, M
    Shigemoto-Mogami, Y
    Koizumi, S
    Inoue, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2003, 91 : 187P - 187P
  • [7] SB203580, the p38 mitogen-activated protein kinase inhibitor blocks the inhibitory effect of β-amyloid on long-term potentiation in the rat hippocampus
    Saleshando, G
    O'Connor, JJ
    NEUROSCIENCE LETTERS, 2000, 288 (02) : 119 - 122
  • [8] The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus
    Jin, Na
    Wang, Qi
    Zhang, Xing
    Jiang, Donghai
    Cheng, Hao
    Zhu, Kejian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (09) : 1319 - 1326
  • [9] p38 Mitogen-activated protein kinase inhibitor SB203580 reverses the antianalgesia induced by dextro-morphine or morphine in the mouse spinal cord
    Wu, Hsiang-en
    Sun, Han-Sen
    Cheng, Caleb W.
    Tseng, Leon F.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 550 (1-3) : 91 - 94
  • [10] SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat
    Stirling, D. P.
    Liu, J.
    Plunet, W.
    Steeves, J. D.
    Tetzlaff, W.
    NEUROSCIENCE, 2008, 155 (01) : 128 - 137
12345